Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Prolong Pharmaceuticals announced today that it has completed enrollment in its Phase II study to evaluate SANGUINATE® in the treatment of...
Prolong Pharmaceuticals LLC, a biopharmaceutical company dedicated to developing products for the treatment of anemia resulting from oxygen...
Prolong Pharmaceuticals today announced that Tom Flachmeyer has joined Prolong to spearhead the firms' engineering and facilities planning function...
Dr. Abraham Abuchowski, CEO and Scientific Founder of Prolong Pharmaceuticals, was honored by the U.S. Small Business Administration on February 15...
Prolong Pharmaceuticals, which in October secured a $30 million funding commitment from a private investment group, today announced the signing of a...
Prolong Pharmaceuticals, which last month announced a $30 million funding commitment from a private investor group, today announced the formal...
Prolong Pharmaceuticals today announced that the company has received a commitment of $30 million in funding from a private investor group. The...
Prolong Pharmaceuticals today announced that industry veteran Glenn Kazo has assumed the title of President. Mr. Kazo has been consulting in various...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.